

## Finance Committee Chair's Highlight Report to Trust Board

<b>Subject:</b>	Finance Committee (FC) Report	<b>Date:</b> 19 December 2023
<b>Prepared By:</b>	Graham Ward – FC Chair	
<b>Approved By:</b>		
<b>Presented By:</b>	Graham Ward – FC Chair	
<b>Purpose:</b>	To provide an overview of the key discussion items from the Finance Committee meeting of 19 December 2023.	
	<b>Assurance</b>	Significant

<b>Matters of Concern or Key Risks to Escalate</b>	<b>Major Actions Commissioned / Work Underway</b>
<ul style="list-style-type: none"> <li>• <u>Month 8 Finance Report</u> – The deficit year to date is £12.5M (£3.0M adverse to plan). Key issues for escalation: <ul style="list-style-type: none"> <li>○ Month 8 Performance – this shows a reduced run rate in line with planned actions which helped deliver a £0.22M surplus in month (£0.82M favourable variance to the planned deficit).</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• <u>Financial Recovery Cabinet</u> – January’s meeting will include a more detailed review of the progress on the 4 workstreams.</li> <li>• <u>Cash</u> – A separate briefing to be arranged for Committee Member NEDs on ‘Cash and the NHS’ in January.</li> <li>• <u>Procurement</u> – A strategy paper for pathology related procurements to be prepared and tabled at a future Committee Meeting.</li> </ul>
<b>Positive Assurances to Provide</b>	<b>Decisions Made (include BAF review outcomes)</b>
<ul style="list-style-type: none"> <li>• <u>H2 Financial resubmission</u> – Recognised the work undertaken to deliver the resubmission and the ongoing discussions subsequent to the submission. Current position shows a forecast deficit for the Trust of £8.5M. Key next step focus is on the 2023/24 exit run rate.</li> <li>• <u>Financial Planning &amp; Budgeting</u> – progress and timetable were noted Committee looked forward to reviewing future progress.</li> <li>• <u>Procurement Forward View</u> – assurance gained on the increased visibility and controls/strategic review being implemented on future procurements.</li> <li>• <u>National Cost Collection</u> – Noted that the submission had been made on time.</li> </ul>	<ul style="list-style-type: none"> <li>• <u>PFI Settlement</u> – the Committee agreed a recommendation to Board to approve the PFI Settlement Agreement subject to: <ul style="list-style-type: none"> <li>○ Satisfactory completion of all the legal documents;</li> <li>○ Agreement of the <u>Performance Management Plan</u> which governs the quality assurance regime.</li> <li>○ The issue and agreement of the <u>ANPR service</u> including the risk share on car parking income.</li> <li>○ Agreement on responsibility for, and cost of, <u>maintenance of catering equipment</u>.</li> <li>○ Finalisation and agreement of the <u>water interventions paper</u>.</li> </ul> </li> <li>• <u>Phoenix Team, Tobacco Dependence Treatment Service Business Case</u> – business case was approved (financed either by NHSR, the division or the Trust funding).</li> <li>• <u>Clinical Research Facility</u> – Business Case was approved.</li> </ul>

- BAF – An initial review ahead of more detailed reviews of PR4 (Financial Strategy) and PR8 (sustainability) in January were undertaken. Comments to be considered by the Senior Executive Team were consideration of an increase to Amber for the Assurance Rating on PR4 and potential reduction of current risk exposure to 16. With respect to PR8 it was considered that this needed a thorough review and reconsideration of the risks and assurance rating.

**Comments on Effectiveness of the Meeting**

- All papers were of a high quality and clear which helped the meeting run smoothly and promoted good constructive challenge and discussion.